Aktis Oncology, Inc. (AKTS) vs LB Pharmaceuticals Inc (LBRX)

Aktis Oncology, Inc. and LB Pharmaceuticals Inc are both Biotechnology companies. LB Pharmaceuticals Inc is the larger, with a market value of $1.2B against $1.1B — 1.1× the size. LB Pharmaceuticals Inc has the higher net margin (0.00% vs −782.0%) and the lower return on invested capital (−1,304.8% vs 0.00%). Across the 12 metrics below, Aktis Oncology, Inc. leads on 6 and LB Pharmaceuticals Inc on 6.

Valuation

Metric AKTS LBRX Biotechnology median
P/E n/m n/m 7.88
P/S 112.39 n/m 11.47
P/B 2.24 3.39 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 58.83 n/m 10.73
Earnings yield (212.97%) (9.22%) (28.84%)
Free cash flow yield (12.84%) (7.36%) (23.03%)

Profitability

Metric AKTS LBRX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (939.13%) 0.00% 0.00%
Net margin (781.95%) 0.00% 0.00%
Free cash flow margin (1,442.91%) 0.00% 0.00%
Return on equity (34.45%) (72.07%) (57.72%)
Return on assets (27.09%) (47.38%) (49.22%)
Return on invested capital 0.00% (1,304.79%) 0.00%

Growth

Metric AKTS LBRX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (25.43%) 98.22% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AKTS LBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.33 15.08 4.73
Net debt to EBITDA 2.95 9.90 0.96

Dividend

Metric AKTS LBRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — — 0.00

Size

Metric AKTS LBRX Biotechnology median
Market cap 1.09b 1.22b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack